Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Average Rating of “Buy” from Brokerages

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has earned an average recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $56.00.

TARS has been the subject of a number of recent analyst reports. Guggenheim reiterated a “buy” rating on shares of Tarsus Pharmaceuticals in a research report on Monday, February 10th. Barclays increased their price objective on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a report on Monday, January 27th. Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, January 22nd. Finally, The Goldman Sachs Group lifted their target price on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th.

Tarsus Pharmaceuticals Trading Up 1.3 %

Shares of TARS stock opened at $50.85 on Wednesday. The firm has a market capitalization of $1.94 billion, a PE ratio of -13.35 and a beta of 1.01. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28. The stock has a fifty day moving average of $52.06 and a two-hundred day moving average of $42.19.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several large investors have recently modified their holdings of TARS. Toronto Dominion Bank purchased a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at $105,714,000. Jennison Associates LLC lifted its stake in Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock valued at $71,653,000 after buying an additional 698,712 shares in the last quarter. Lord Abbett & CO. LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 115.2% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock worth $70,873,000 after buying an additional 685,111 shares during the period. Millennium Management LLC increased its position in shares of Tarsus Pharmaceuticals by 189.4% in the fourth quarter. Millennium Management LLC now owns 644,010 shares of the company’s stock worth $35,659,000 after acquiring an additional 421,495 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after acquiring an additional 420,057 shares during the period. 90.01% of the stock is owned by institutional investors.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.